Bio-Rad Laboratories, Inc. (BIO) Earnings History
Earnings Pressure37 years of earnings data (1989–2025) · 5-year EPS trend is negative
Loading earnings history...
Bio-Rad Laboratories, Inc. (BIO) Earnings Overview
As of October 3, 2026, Bio-Rad Laboratories, Inc. (BIO) reported trailing twelve-month net income of $222M, reflecting +142.6% year-over-year growth. The company earned $8.29 per diluted share over the past four quarters, with a net profit margin of 29.4%.
Looking at the long-term picture, BIO's 5-year EPS compound annual growth rate (CAGR) stands at -26.1%, signaling declining earnings. The company achieved its highest annual net income of $4.25B in fiscal 2021.
Bio-Rad Laboratories, Inc. maintains industry-leading profitability with a gross margin of 52.0%, operating margin of 10.5%, and net margin of 29.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including TMO ($6.98B net income, 15.1% margin), DHR ($4.00B net income, 14.7% margin), BRKR (-$71M net income, -0.3% margin), BIO has outperformed on profitability metrics. Compare BIO vs TMO →
BIO Earnings vs Peers
Earnings metrics vs comparable public companies
BIO Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $760M | +141.2% | $271M | $27.87 | 29.4% | 10.5% |
| 2024 | -$1.84B | -189.4% | $269M | $-65.36 | -71.9% | 10.5% |
| 2023 | -$637M | +82.4% | $338M | $-21.82 | -23.9% | 12.6% |
| 2022 | -$3.63B | -185.3% | $483M | $-121.79 | -129.5% | 17.2% |
| 2021 | $4.25B | +11.5% | $500M | $140.83 | 145.6% | 17.1% |
| 2020 | $3.81B | +116.9% | $421M | $126.20 | 149.8% | 16.6% |
| 2019 | $1.76B | +387.2% | $230M | $58.27 | 76.1% | 9.9% |
| 2018 | $361M | +214.6% | -$109M | $11.94 | 15.8% | -4.7% |
| 2017 | $115M | +308.0% | $117M | $4.07 | 5.3% | 5.4% |
| 2016 | $28M | -75.1% | $53M | $0.88 | 1.4% | 2.6% |
| 2015 | $113M | +27.3% | $167M | $3.71 | 5.6% | 8.3% |
| 2014 | $89M | +14.2% | $150M | $3.05 | 4.1% | 6.9% |
| 2013 | $78M | -54.0% | $169M | $2.69 | 3.6% | 7.9% |
| 2012 | $169M | -5.0% | $264M | $5.78 | 8.2% | 12.8% |
| 2011 | $178M | -3.9% | $295M | $6.29 | 8.6% | 14.2% |
| 2010 | $185M | +28.3% | $284M | $6.59 | 9.6% | 14.7% |
| 2009 | $145M | +61.6% | $231M | $5.20 | 8.1% | 12.9% |
| 2008 | $90M | -3.7% | $183M | $3.24 | 5.1% | 10.4% |
| 2007 | $93M | -9.9% | $135M | $3.41 | 6.4% | 9.3% |
| 2006 | $103M | +26.6% | $146M | $3.83 | 8.1% | 11.5% |
| 2005 | $82M | +19.5% | $115M | $3.06 | 6.9% | 9.8% |
| 2004 | $68M | -10.4% | $109M | $2.58 | 6.3% | 10.0% |
| 2003 | $76M | +12.2% | $146M | $2.90 | 7.6% | 14.5% |
| 2002 | $68M | +53.6% | $137M | $2.61 | 7.6% | 15.4% |
| 2001 | $44M | +42.1% | $112M | $1.74 | 5.4% | 13.7% |
| 2000 | $31M | +165.8% | $67M | $1.27 | 4.3% | 9.2% |
| 1999 | $12M | -51.9% | $49M | $0.48 | 2.1% | 8.8% |
| 1998 | $24M | +48.2% | $31M | $0.99 | 5.5% | 7.0% |
| 1997 | $16M | -37.4% | $27M | $0.66 | 3.8% | 6.2% |
| 1996 | $26M | +4.0% | $42M | $1.05 | 6.3% | 10.0% |
| 1995 | $25M | +61.5% | $40M | $1.03 | 6.4% | 10.0% |
| 1994 | $16M | +457.1% | $37M | $0.64 | 4.4% | 10.3% |
| 1993 | $3M | -82.1% | $10M | $0.12 | 0.9% | 3.2% |
| 1992 | $16M | +90.2% | $15M | $0.66 | 4.7% | 4.4% |
| 1991 | $8M | -23.4% | $22M | $0.35 | 2.6% | 7.1% |
| 1990 | $11M | +5.9% | $24M | $0.46 | 3.7% | 8.5% |
| 1989 | $10M | - | $21M | $0.45 | 4.3% | 8.9% |
Download Data
Export BIO earnings history in CSV or JSON format
Free sign-in required to download data
BIO Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BIO — Frequently Asked Questions
Quick answers to the most common questions about buying BIO stock.
What is BIO earnings per share (EPS)?
BIO trailing twelve-month (TTM) diluted EPS is $8.29, reflecting +142.6% year-over-year growth. The 5-year EPS CAGR is -26.1%. Complete EPS history from 1989 to 2025 is available in the table on this page.
What is Bio-Rad Laboratories, Inc.'s net income?
Bio-Rad Laboratories, Inc. (BIO) trailing twelve-month net income is $222M as of 2025. Earnings grew +142.6% year-over-year.
Is BIO profitable?
Yes, BIO is profitable with a TTM net income of $222M and a net profit margin of +29.4%.
What is BIO's earnings growth rate?
BIO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: -26.1%, 10-Year: +22.3%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.
What are BIO's profit margins?
Bio-Rad Laboratories, Inc. net profit margin is +29.4%, operating margin is +10.5%, and gross margin is +52.0%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +10.8%.
Is BIO growing earnings?
Yes, BIO earnings are accelerating — EPS growth of +142.6% exceeds the 5-year CAGR of -26.1%. TTM net income reached $222M. Earnings momentum is strengthening.
What was BIO's best earnings year?
Bio-Rad Laboratories, Inc.'s highest annual net income on record is $4.3B, achieved in fiscal year 2021. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.
What were BIO's earnings last quarter?
BIO's most recent reported quarter was Q2 2026. Net income was $371M with diluted EPS of $13.85. For a full breakdown of all quarters, see the quarterly earnings table on this page.